June 19, 2020 / 1:57 PM / a month ago

Glenmark gets India approval for favipiravir as COVID-19 treatment

BENGALURU, June 19 (Reuters) - Glenmark Pharmaceuticals Ltd said on Friday it had received an approval from India’s drugs regulator to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 patients in the country.

The Mumbai-based drugmaker said the approval was part of India's accelerated approval process and the drug would be for "restricted emergency use" in the country. (bit.ly/310MByO)

Favipiravir is made under the brand name Avigan by Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014. (Reporting by Sachin Ravikumar; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below